Emergent BioSolutions Inc.

NYSE:EBS 株式レポート

時価総額：US$481.2m

Emergent BioSolutions 将来の成長

Future 基準チェック /46

Emergent BioSolutionsの収益は年間0.7%で減少すると予測されていますが、年間利益は年間98.5%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に28.4% 98.6%なると予測されています。

主要情報

98.5%

収益成長率

98.6%

EPS成長率

Biotechs 収益成長28.4%
収益成長率-0.7%
将来の株主資本利益率28.4%
アナリストカバレッジ

Low

最終更新日07 Nov 2024

今後の成長に関する最新情報

Recent updates

Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth

Nov 09
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Nov 08

Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Oct 04

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 18

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process

Jul 15

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

May 10

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Dec 18

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Nov 23

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Aug 23

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Aug 14

Emergent BioSolutions: Making A Big Bet On Narcan

Jul 21

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

業績と収益の成長予測

NYSE:EBS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20261,08113N/AN/A1
12/31/20251,196491661831
12/31/20241,108-182146601
9/30/20241,126-209138171N/A
6/30/20241,102-5873177N/A
3/31/20241,185-565-138-85N/A
12/31/20231,049-760-264-206N/A
9/30/20231,103-778-216-146N/A
6/30/20231,072-602-602-280N/A
3/31/2023974-394-523-181N/A
12/31/20221,118-212-394-34N/A
9/30/20221,49133-180201N/A
6/30/20221,58188127292N/A
3/31/20221,75715878279N/A
12/31/20211,77422096320N/A
9/30/20211,65322723237N/A
6/30/20211,709299121326N/A
3/31/20211,706387300483N/A
12/31/20201,577306385537N/A
9/30/20201,333167262413N/A
6/30/20201,259170184305N/A
3/31/20201,1086841141N/A
12/31/20191,1065591188N/A
9/30/20191,0164-181-100N/A
6/30/2019878-18-1577N/A
3/31/20198554266148N/A
12/31/201878263-3042N/A
9/30/2018706100221285N/A
6/30/2018681113N/A146N/A
3/31/201856267N/A165N/A
12/31/201756183N/A208N/A
9/30/201751981N/A118N/A
6/30/201751268N/A110N/A
3/31/201750361N/A54N/A
12/31/201648963N/A55N/A
9/30/201649773N/A70N/A
6/30/201651294N/A148N/A
3/31/2016529125N/A153N/A
12/31/201548991N/A43N/A
9/30/201547879N/A93N/A
6/30/201545759N/A67N/A
3/31/201546035N/A76N/A
12/31/201440454N/A112N/A
9/30/201440022N/A69N/A
6/30/201435114N/A50N/A
3/31/201432419N/A72N/A
12/31/201331331N/A97N/A

アナリストによる今後の成長予測

収入対貯蓄率: EBSは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: EBS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EBS今後 3 年以内に収益を上げることが予想されます。

収益対市場: EBSの収益は今後 3 年間で減少すると予想されています (年間-0.7% )。

高い収益成長: EBSの収益は今後 3 年間で減少すると予測されています (年間-0.7% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EBSの 自己資本利益率 は、3年後には高くなると予測されています ( 28.4 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y